Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...